4.7 Article

Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 139, Issue -, Pages 836-848

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.08.058

Keywords

Celastrol; Triterpenes; Carbamates; Cytotoxicity; Apoptosis; Drug synergy

Funding

  1. Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/86163/2012]
  2. FEDER (European Regional Development Fund) through COMPETE 2020 Programme (Operational Programme for Competitiveness and Internationalisation) [CENTRO-01-0247-FEDER-003269]
  3. FEDER through COMPETE 2020 Programme
  4. National Funds through FCT [UID/NEU/04539/2013, REEQ1481/QUI/2006, RECI/QEQ-QFI/0168/2012, CENTRO-07-CT62- FEDER-002012]
  5. European Union Una manera de hacer Europa [SAF2014-56059-R, SAF2015-70270-REDT]
  6. Generalitat de Catalunya-AGAUR [2014SGR1017]
  7. ICREA Academia Award
  8. Rede Nacional de Ressonancia Magnetica Nuclear (RNRMN)
  9. Spanish Government
  10. Fundação para a Ciência e a Tecnologia [SFRH/BD/86163/2012] Funding Source: FCT

Ask authors/readers for more resources

Celastrol and its derivatives have been reported for their potent anticancer activity. Among other celastrol analogues, novel carbamate derivatives were designed and synthesised, and their biological activity on the viability of human cancer cell lines was evaluated. Additionally, a preliminary structure activity relationship study was conducted. Derivative 18 showed the highest activity on cancer cell viability, combined with the best selectivity between malignant cells and non-malignant fibroblasts. Preliminary mechanistic studies of its anti-tumour action indicated that compound 18 has an anti proliferative effect on SKOV-3 human ovarian cancer cells (IC50 = 0.54 mu M). The results also suggested that its potent anticancer activity is mediated by apoptosis, and that this process was mainly the result of the activation of the extrinsic apoptotic pathway. Moreover, our results demonstrated the potential of derivative 18 as a new agent for combinatorial drug therapy for ovarian cancer. (C) 2017 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available